Compare Abbott Laboratories (ABT) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Vanguard High Dividend Yield ETF — how do they compare? Abbott Laboratories trades at $109.6 (market cap $187.95B), while Vanguard High Dividend Yield ETF trades at $166.5. The key difference: Abbott Laboratories pays a 2.32% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | VYM | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $166.14 |
52-Week Low | $82.57 | $136.63 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
VYM trades at $165.63, up 0.52% today, near its 52-week high with strong bullish momentum from moving averages. The ETF's technicals show overbought RSI signals but positive ADX trends, while recent news highlights its role in retirement income strategies. A dividend of $0.98 is scheduled for June 2026, reinforcing its income focus amid institutional adjustments.
Outlook remains positive for income-seeking investors due to VYM's dividend reliability and sector diversification, though overbought conditions and underperformance versus the S&P 500 pose risks. Key opportunities include sustainable yield; risks involve market volatility and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
